The immunomodulatory potential of mesenchymal stromal cells: A story of a regulatory network

Journal of Immunotherapy

Volumn 39, Issue 2, 2016, Pages 45-59

  Najar, Mehdi ^a   Raicevic, Gordana ^a   Crompot, Emerence ^a   Fayyad Kazan, Hussein ^a   Bron, Dominique ^a   Toungouz, Michel ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Immune system; Immunomodulation; Immunotherapy; Mediators; Mesenchymal stromal cells; Regulatory network; Tolerance

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; CYTOKINE; EPHRIN; EPHRIN RECEPTOR; GALECTIN; GAMMA INTERFERON; HEME OXYGENASE 1; HLA G ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SEMAPHORIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA STIMULATED PROTEIN 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW STROMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; HISTOCOMPATIBILITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; T LYMPHOCYTE; BONE MARROW; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; STROMA CELL;

BONE MARROW; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INTERLEUKIN-10; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; STROMAL CELLS; T-LYMPHOCYTES;

EID: 84958012813     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000108     Document Type: Review

References (219)

1. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guineapig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393-403.
2. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
3. Hoogduijn MJ, Betjes MG, Baan CC. Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics? Curr Opin Organ Transplant. 2014;19:41-46.
4. Phinney DG, Sensebé L. Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy. 2013;15:140-145.
5. Horwitz EM, Le Blanc K, Dominici M, et al. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393-395.
6. DominiciM, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
7. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther. 2007;9: 204.
8. Sharma RR, Pollock K, Hubel A, et al. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014;54:1418-1437.
9. Cao W, Cao K, Cao J, et al. Mesenchymal stem cells and adaptive immune responses. Immunol Lett. 2015. pii: S0165-2478(15)00101-7. doi: 10.1016/j.imlet.2015.06.003.
10. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87-117.
11. Amorin B, Alegretti AP, Valim V, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum Cell. 2014;27:137-150.
12. KramperaM, Galipeau J, Shi Y, et al. MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells - The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013;15:1054-1061.
13. Wang L, Zhao Y, Shi S. Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J Dent Res. 2012;91:1003-1010.
14. Najar M, Rouas R, Raicevic G, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11: 570-583.
15. Majumdar MK, Keane-Moore M, Buyaner D, et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 2003; 10:228-241.
16. Najar M, Raicevic G, Id Boufker H, et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol. 2010;38:922-932.
17. Najar M, Raicevic G, Fayyad-Kazan H, et al. Immunerelated antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev. 2012;8:1188-1198.
18. Ryan JM, Barry FP, Murphy JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.
19. Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011;2:34.
20. Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol. 2012;3:212.
21. Gieseke F, Schütt B, Viebahn S, et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood. 2007;110:2197-2200.
22. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther. 2010;1:34.
23. Najar M, Raicevic G, Jebbawi F, et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett. 2012;146:50-56.
24. BassiÊ J, de Almeida DC, Moraes-Vieira PM, et al. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev. 2012;8:329-342.
25. Nguyen TM, Arthur A, Hayball JD, et al. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. Stem Cells Dev. 2013;22: 2751-2764.
26. Carrillo-Gá lvez AB, Cobo M, Cuevas-Ocañ a S, et al. Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacity. Stem Cells. 2015;33:183-195.
27. Amarnath S, Foley JE, Farthing DE, et al. Bone marrow derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells. 2015;33:1200-1212.
28. Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216-225.
29. Su J, Chen X, Huang Y, et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2014;21:388-396.
30. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010; 28:585-596.
31. Striz I, Brabcova E, Kolesar L, et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond). 2014;126:593-612.
32. Lippolis JD. Immunological signaling networks: integrating the body's immune response. J Anim Sci. 2008;86(suppl): E53-E63.
33. Mattila JT, Thomas AC. Nitric oxide synthase: non-canonical expression patterns. Front Immunol. 2014;5:478.
34. Wink DA, Hines HB, Cheng RY, et al. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011;89: 873-891.
35. Bonafè F, Guarnieri C, Muscari C. Nitric oxide regulates multiple functions and fate of adult progenitor and stem cells. J Physiol Biochem. 2015;71:141-153.
36. Yan K, Zhang R, Chen L, et al. Nitric oxide-mediated immunosuppressive effect of human amniotic membranederived mesenchymal stem cells on the viability and migration of microglia. Brain Res. 2014;1590:1-9.
37. Zhang L, Dang RJ, Li H, et al. SOCS1 regulates the immune modulatory properties of mesenchymal stem cells by inhibiting nitric oxide production. PLoS One. 2014;9: e97256.
38. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27:1954-1962.
39. Yen BL, Yen ML, Hsu PJ, et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloidderived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Reports. 2013;1:139-151.
40. Felka T, Ulrich C, Rolauffs B, et al. Nitric oxide activates signaling by c-Raf, MEK, p-JNK, p38 MAPK and p53 in human mesenchymal stromal cells and inhibits their osteogenic differentiation by blocking expression of Runx2. J Stem Cell Res Ther. 2014;4:195.
41. Huang CJ, Stevens BR, Nielsen RB, et al. Interleukin-10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription. Nitric Oxide. 2002;6:79-84.
42. Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2015; 55:465-487.
43. Funk SD, Orr AW. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol Res. 2013;67: 42-52.
44. Xing W, Kim J, Wergedal J, et al. Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol. 2010;30:711-721.
45. Arthur A, Zannettino A, Panagopoulos R, et al. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone. 2011;48: 533-542.
46. Oike Y, Ito Y, Hamada K, et al. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood. 2002;100:1326-1333.
47. To C, Farnsworth RH, Vail ME, et al. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS One. 2014;9:e112106.
48. Barbet R, Peiffer I, Hatzfeld A, et al. Comparison of gene expression in human embryonic stem cells, hESC-derived mesenchymal stem cells and human mesenchymal stem cells. Stem Cells Int. 2011;2011:368192.
49. Wang R, Zhu J, Dong X, et al. GARP regulates the bioavailability and activation of TGFb. Mol Biol Cell. 2012; 23:1129-1139.
50. Stockis J, Colau D, Coulie PG, et al. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol. 2009;39:3315-3322.
51. Hahn SA, Stahl HF, Becker C, et al. Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. Blood. 2013;122:1182-1191.
52. Roney K, Holl E, Ting J. Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell. 2013;4: 17-26.
53. Kumanogoh A, Kikutani H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol. 2013;13:802-814.
54. Lepelletier Y, Lecourt S, Renand A, et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev. 2010;19:1075-1079.
55. Catalano A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol. 2010;185:6373-6383.
56. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199-236.
57. Gibson JM, Aplin JD, White A, et al. Regulation of IGF bioavailability in pregnancy. Mol Hum Reprod. 2001;7:79-87.
58. Patel AV, Cheng I, Canzian F, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008;3:e2578.
59. Katz J, Nasatzky E, Werner H, et al. Tumor necrosis factor alpha and interferon gamma - induced cell growth arrest is mediated via insulin-like growth factor binding protein-3. Growth Horm IGF Res. 1999;9:174-178.
60. Amable PR, Teixeira MV, Carias RB, et al. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly. Stem Cell Res Ther. 2014;5:53.
61. Kooijman R, Coppens A. Insulin-like growth factor-I stimulates IL-10 production in human T cells. J Leukoc Biol. 2004;76:862-867.
62. Gorczynski RM. CD200:CD200R-mediated regulation of immunity. ISRN Immunology. 2012;2012:18.
63. Pietilä M, Lehtonen S, Tuovinen E, et al. CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells. PLoS One. 2012;7:e31671.
64. Rosenblum MD, Olasz E, Woodliff JE, et al. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood. 2004;103:2691-2698.
65. Lee TH, Wisniewski HG, Vilcek J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol. 1992;116:545-557.
66. Wisniewski HG, Vilcek J. TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev. 1997;8:143-156.
67. Kota DJ, Wiggins LL, Yoon N, et al. TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes. 2013;62:2048-2058.
68. Liu Y, Zhang R, Yan K, et al. Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6. J Neuroinflammation. 2014; 11:135.
69. Liu S, Jiang L, Li H, et al. Mesenchymal stem cells prevent hypertrophic scar formation via inflammatory regulation when undergoing apoptosis. J Invest Dermatol. 2014;134: 2648-2657.
70. Lee RH, Oh JY, Choi H, et al. Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. J Cell Biochem. 2011;112:3073-3078.
71. Lee RH, Yu JM, Foskett AM, et al. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A. 2014;111:16766-16771.
72. Liu FT. Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol. 2005;136:385-400.
73. Sioud M, Mobergslien A, Boudabous A, et al. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol. 2011;38:385-390.
74. Liu GY, Xu Y, Li Y, et al. Secreted galectin-3 as a possible biomarker for the immunomodulatory potential of human umbilical cord mesenchymal stromal cells. Cytotherapy. 2013; 15:1208-1217.
75. Rabinovich GA, Toscano MA. Turning "sweet" on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9:338-352.
76. Garín MI, Chu CC, Golshayan D, et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109:2058-2065.
77. Gieseke F, Böhringer J, Bussolari R, et al. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. 2010;116:3770-3779.
78. Gieseke F, Kruchen A, Tzaribachev N, et al. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol. 2013;43:2741-2749.
79. Wiersma VR, de Bruyn M, Helfrich W, et al. Therapeutic potential of Galectin-9 in human disease. Med Res Rev. 2013;33(suppl 1):E102-E126.
80. Ungerer C, Quade-Lyssy P, Radeke HH, et al. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 2014;23:755-766.
81. Cedeno-Laurent F, Opperman M, Barthel SR, et al. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 2012;188: 3127-3137.
82. Lee YJ, Song YK. Cooperative interaction between interleukin 10 and galectin-3 against liver ischemia-reperfusion injury. Clin Cancer Res. 2002;8:217-220.
83. Chabannes D, Hill M, Merieau E, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood. 2007;110: 3691-3694.
84. Mougiakakos D, Jitschin R, Johansson CC, et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011;117:4826-4835.
85. Patel SR, Copland IB, Garcia MA, et al. Human mesenchymal stromal cells suppress T-cell proliferation independent of heme oxygenase-1. Cytotherapy. 2015;17:382-391.
86. Blancou P, Anegon I. Editorial: heme oxygenase-1 and dendritic cells: what else? J Leukoc Biol. 2010;87:185-187.
87. Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007;35:7074-7086.
88. Lee TS, Chau LY. Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat Med. 2002;8:240-246.
89. Li JG, Zhuan-sun YX, Wen B, et al. Human mesenchymal stem cells elevate CD4+CD25+CD127low/-regulatory T cells of asthmatic patients via heme oxygenase-1. Iran J Allergy Asthma Immunol. 2013;12:228-235.
90. Zarjou A, Kim J, Traylor AM, et al. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol. 2011; 300:F254-F262.
91. Chen KD, Hsu LW, Goto S, et al. Regulation of heme oxygenase 1 expression by miR-27b with stem cell therapy for liver regeneration in rats. Transplant Proc. 2014;46: 1198-1200.
92. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67:1-8.
93. Skibinski G. The role of hepatocyte growth factor/c-met interactions in the immune system. Arch Immunol Ther Exp (Warsz). 2003;51:277-282.
94. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
95. Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 2005;19: 1597-1604.
96. Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 2010;264:171-179.
97. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10+ +IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006;108:218-227.
98. Chen PM, Liu KJ, Hsu PJ, et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2. J Leukoc Biol. 2014;96:295-303.
99. Schröder K, Schütz S, Schlöffel I, et al. Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. Antioxid Redox Signal. 2011;15:915-923.
100. Mizuno S, Nakamura T. Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential. Gastroenterol Res Pract. 2012;2012:909350.
101. Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL-6 and IL-10 balance by HGF via recruitment of heme oxygenase-1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. Int J Mol Med. 2009;24: 161-170.
102. Neuss S, Becher E, Wöltje M, et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells. 2004;22:405-414.
103. Bai L, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci. 2012;15:862-870.
104. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
105. Nasef A, Chapel A, Mazurier C, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of Tlymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007;13:217-226.
106. Groh ME, Maitra B, Szekely E, et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005;33:928-934.
107. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-397.
108. Cosmi L, Liotta F, Maggi E, et al. Th17 cells: new players in asthma pathogenesis. Allergy. 2011;66:989-998.
109. Nemeth K, Keane-Myers A, Brown JM, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A. 2010;107:5652-5657.
110. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8:1390-1397.
111. Sun Z, Han Q, Zhu Y, et al. NANOG has a role in mesenchymal stem cells' immunomodulatory effect. Stem Cells Dev. 2011;20:1521-1528.
112. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem. 1996;271:33157-33160.
113. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21-28.
114. Kleiveland CR, Kassem M, Lea T. Human mesenchymal stem cell proliferation is regulated by PGE2 through differential activation of cAMP-dependent protein kinase isoforms. Exp Cell Res. 2008;314:1831-1838.
115. Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol. 2010;10: 1496-1500.
116. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105: 1815-1822.
117. Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005; 305:33-41.
118. Yu KR, Lee JY, Kim HS, et al. A p38 MAPK-mediated alteration of COX-2/PGE2 regulates immunomodulatory properties in human mesenchymal stem cell aging. PLoS One. 2014;9:e102426.
119. Sá nchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115: 107-121.
120. Lee S, Kim HS, Roh KH, et al. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells. Sci Rep. 2015;5: 8020.
121. Rosca AM, Burlacu A. Effect of 5-azacytidine: evidence for alteration of the multipotent ability of mesenchymal stem cells. Stem Cells Dev. 2011;20:1213-1221.
122. Zhang F, Wu J, Lu M, et al. 5-Azacytidine inhibits proliferation and induces apoptosis of mouse bone marrowderived mesenchymal stem cells. Toxin Reviews. 2013;32: 55-59.
123. Wu YL, Ding YP, Tanaka Y, et al. gd T cells and their potential for immunotherapy. Int J Biol Sci. 2014;10:119-135.
124. Martinet L, Fleury-Cappellesso S, Gadelorge M, et al. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Eur J Immunol. 2009;39: 752-762.
125. Prigione I, Benvenuto F, Bocca P, et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009;27:693-702.
126. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12:47-57.
127. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15: 42-49.
128. Cheon H, Rho YH, Choi SJ, et al. Prostaglandin E2 augments IL-10 signaling and function. J Immunol. 2006;177: 1092-1100.
129. Matysiak M, Orlowski W, Fortak-Michalska M, et al. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol. 2011;233: 106-111.
130. Bouffi C, Bony C, Courties G, et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010;5:e14247.
131. Solchaga LA, Zale EA. Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells. 2012;1:138-145.
132. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222:206-221.
133. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774.
134. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-4621.
135. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia. 2011;25:648-654.
136. Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27:909-919.
137. Usui Y, Okunuki Y, Hattori T, et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res. 2008;86:52-59.
138. Chinnadurai R, Copland IB, Patel SR, et al. IDO-independent suppression of T cell effector function by IFN-g-licensed human mesenchymal stromal cells. J Immunol. 2014;192: 1491-1501.
139. Ryan JM, Barry F, Murphy JM, et al. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-363.
140. Benvenuto F, Ferrari S, Gerdoni E, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells. 2007;25:1753-1760.
141. Maby-El Hajjami H, Amé-Thomas P, Pangault C, et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res. 2009;69:3228-3237.
142. Luo C, Jia W, Wang K, et al. Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways. Curr Stem Cell Res Ther. 2014;9: 36-45.
143. von Bubnoff D, Koch S, Bieber T. New jobs for an old enzyme: the revival of IDO. Trends Immunol. 2003;24: 296-297.
144. Ankrum JA, Dastidar RG, Ong JF, et al. Performanceenhanced mesenchymal stem cells via intracellular delivery of steroids. Sci Rep. 2014;4:4645.
145. Chen X, Gan Y, Li W, et al. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis. 2014;5:e1009.
146. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. 2008;20:55-60.
147. Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312-1320.
148. Kong QF, Sun B, Wang GY, et al. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol. 2009;39:800-809.
149. Ling W, Zhang J, Yuan Z, et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res. 2014;74:1576-1587.
150. Wang D, Feng X, Lu L, et al. A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:2234-2245.
151. Shiina T, Hosomichi K, Inoko H, et al. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54:15-39.
152. Carosella ED, HoWangYin KY, Favier B, et al. HLA-Gdependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol. 2008;69:700-707.
153. Carosella ED, Gregori S, Rouas-Freiss N, et al. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci. 2011;68:353-368.
154. Götherström C, West A, Liden J, et al. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica. 2005;90:1017-1026.
155. Chang CJ, Yen ML, Chen YC, et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006;24:2466-2477.
156. Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010;5:e10088.
157. Siegel G, Schä fer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009; 87(suppl):S45-S49.
158. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869-5885.
159. Teklemariam T, Purandare B, Zhao L, et al. Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem cells. Biochem Biophys Res Commun. 2014;452:753-759.
160. Ivanova-Todorova E, Mourdjeva M, Kyurkchiev D, et al. HLA-G expression is up-regulated by progesterone in mesenchymal stem cells. Am J Reprod Immunol. 2009;62: 25-33.
161. Yang HM, Sung JH, Choi YS, et al. Enhancement of the immunosuppressive effect of human adipose tissue-derived mesenchymal stromal cells through HLA-G1 expression. Cytotherapy. 2012;14:70-79.
162. Boura JS, Vance M, Yin W, et al. Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells. Mol Ther Methods Clin Dev. 2014;2014. pii: 14041.
163. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007;84:231-237.
164. Rizzo R, Campioni D, Stignani M, et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy. 2008;10:364-375.
165. López AS, Alegre E, LeMaoult J, et al. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol. 2006;43:2151-2160.
166. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26:212-222.
167. Carosella ED, Gregori S, LeMaoult J. The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. Blood. 2011;118:6499-6505.
168. Moreau P, Adrian-Cabestre F, Menier C, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol. 1999;11:803-811.
169. Alegre E, Rizzo R, Bortolotti D, et al. Some basic aspects of HLA-G biology. J Immunol Res. 2014;2014:657625.
170. Kanai T, Fujii T, Kozuma S, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod. 2001;7:195-200.
171. Giuliani M, Fleury M, Vernochet A, et al. Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One. 2011;6:e19988.
172. Ketroussi F, Giuliani M, Bahri R, et al. Lymphocyte cellcycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One. 2011;6:e22776.
173. Avanzini MA, Bernardo ME, Cometa AM, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood-and bone marrow-derived progenitors. Haematologica. 2009;94:1649-1660.
174. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted Tcell responses against viral or tumor-associated antigens. Stem Cells. 2008;26:1275-1287.
175. Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol. 2014;5:394.
176. Stubbendorff M, Deuse T, Hua X, et al. Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev. 2013;22:2619-2629.
177. Naji A, Rouas-Freiss N, Durrbach A, et al. Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells. 2013;31:2296-2303.
178. Selmani Z, Naji A, Gaiffe E, et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation. 2009;87(suppl): S62-S66.
179. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells. 2003;21:5-14.
180. Aghajanova L. Leukemia inhibitory factor and human embryo implantation. Ann N Y Acad Sci. 2004;1034:176-183.
181. Linker RA, Kruse N, Israel S, et al. Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J Immunol. 2008;180: 2204-2213.
182. Banner LR, Patterson PH, Allchorne A, et al. Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine. J Neurosci. 1998;18:5456-5462.
183. Thellin O, Coumans B, Zorzi W, et al. Tolerance to the foetoplacental "graft": ten ways to support a child for nine months. Curr Opin Immunol. 2000;12:731-737.
184. Metcalfe SM, Watson TJ, Shurey S, et al. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation. 2005;79:726-730.
185. Nasef A, Zhang YZ, Mazurier C, et al. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol. 2009;31:9-19.
186. Majumdar MK, Thiede MA, Haynesworth SE, et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res. 2000;9:841-848.
187. Jansen BJ, Gilissen C, Roelofs H, et al. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev. 2010;19:481-490.
188. Wetzler M, Talpaz M, Lowe DG, et al. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNFalpha, and TGF-beta. Exp Hematol. 1991;19:347-351.
189. Najar M, Raicevic G, Boufker HI, et al. Adipose-tissuederived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16:3537-3546.
190. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 2008;253:16-22.
191. Bamberger AM, Jenatschke S, Schulte HM, et al. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab. 2000;85:3932-3936.
192. Dallagi A, Girouard J, Hamelin-Morrissette J, et al. The activating effect of IFN-g on monocytes/macrophages is regulated by the LIF-trophoblast-IL-10 axis via Stat1 inhibition and Stat3 activation. Cell Mol Immunol. 2015;12: 326-341.
193. Dechanet J, Taupin JL, Chomarat P, et al. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur J Immunol. 1994;24:3222-3228.
194. Ng TH, Britton GJ, Hill EV, et al. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4: 129.
195. Pierson W, Liston A. A new role for interleukin-10 in immune regulation. Immunol Cell Biol. 2010;88:769-770.
196. Joss A, Akdis M, Faith A, et al. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol. 2000;30:1683-1690.
197. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50.
198. Ivanova-Todorova E, Bochev I, Dimitrov R, et al. Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion. J Biomed Biotechnol. 2012;2012:295167.
199. Burchfield JS, Iwasaki M, Koyanagi M, et al. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res. 2008;103:203-211.
200. Bishopric NH. Mesenchymal stem cell-derived IL-10 and recovery from infarction: a third pitch for the chord. Circ Res. 2008;103:125-127.
201. Wong CK, Wong PT, Tam LS, et al. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010;159:11-22.
202. Suzuki S, Mita S, Kamohara H, et al. IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol. 2001;18:581-586.
203. Foey AD, Parry SL, Williams LM, et al. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNFalpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol. 1998;160:920-928.
204. Najar M, Raicevic G, Fayyad-Kazan H, et al. Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210 axis. Stem Cell Rev. 2015;11:442-452.
205. van den Bosch MW, Palsson-Mcdermott E, Johnson DS, et al. LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production. J Biol Chem. 2014;289:22980-22990.
206. Lo Furno D, Graziano AC, Caggia S, et al. Decrease of apoptosis markers during adipogenic differentiation of mesenchymal stem cells from human adipose tissue. Apoptosis. 2013;18:578-588.
207. Suva D, Passweg J, Arnaudeau S, et al. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol. 2008;214:588-594.
208. Payne NL, Sun G, McDonald C, et al. Human adiposederived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun. 2013;30:103-114.
209. Prevosto C, Zancolli M, Canevali P, et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92: 881-888.
210. Rizzo R, Hviid TV, Stignani M, et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics. 2005;57:172-181.
211. Milwid JM, Elman JS, Li M, et al. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther. 2014;22:999-1007.
212. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxininduced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106:16357-16362.
213. Zhang X, Ren X, Li G, et al. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Invest Ophthalmol Vis Sci. 2011;52:3143-3152.
214. Bustos ML, Huleihel L, Meyer EM, et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med. 2013;2:884-895.
215. Wu H, Wen D, Mahato RI. Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model. Mol Ther. 2013;21:1778-1786.
216. Swart JF, de Roock S, Hofhuis FM, et al. Mesenchymal stem cell therapy in proteoglycan induced arthritis. Ann Rheum Dis. 2015;74:769-777.
217. Quinn SR, O'Neill LA. The role of microRNAs in the control and mechanism of action of IL-10. Curr Top Microbiol Immunol. 2014;380:145-155.
218. Yan Z, Zhuansun Y, Liu G, et al. Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions. Immunol Lett. 2014;162(pt A):248-255.
219. Prockop DJ. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells. 2013;31: 2042-2046.